Back
CT.gov ↗CT.gov ↗CT.gov ↗CT.gov ↗8-K ↗8-K ↗8-K ↗
KRYS
Krystal Biotech, Inc.
Krystal Biotech develops gene therapies using a proprietary herpes simplex virus (HSV-1) based vector platform, primarily focused on genetic skin diseases. The company's lead product, VYJUVEK, was approved by the FDA in May 2023 and the European Commission in April 2025 for treating dystrophic epidermolysis bullosa (DEB), and it is now in the commercialization stage across the United States, European Union, Japan, and other markets.
$262.26+54.38%1Y
KRYS · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Dystrophic Epidermolysis Bullosa
Phase 3DEB - Dystrophic Epidermolysis Bullosa
Phase 3Recessive Dystrophic Epidermolysis Bullosa
Phase 3Dominant Dystrophic Epidermolysis Bullosa
Phase 2Lung Cancer, Non-small Cell
Phase 2Lung Cancer Metastatic
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
Generic 'chemotherapy' label without a specific agent identified. Indicates a cytotoxic regimen used as comparator or backbone.
Phase 2Lung Cancer, Non-small Cell
Phase 2Lung Cancer Metastatic
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
Taxane chemotherapy that stabilizes microtubules and arrests mitosis. Used in breast, prostate, NSCLC, head and neck, and gastric cancers.
Phase 2Wrinkles in Decolletage
Phase 2Pigmentation
Phase 2Décolleté Wrinkles
Unknownmoderate to severe wrinkles of the décolleté
Phase 2Lung Cancer Metastatic
Phase 2Lung Cancer, Non-small Cell
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
Phase 2Cancer
Phase 2Melanoma Stage III
Phase 2Melanoma Stage IV
Phase 2Cutaneous Melanoma
Phase 2Neurotrophic Keratitis
Phase 2Cancer
Phase 2Melanoma Stage III
Phase 2Melanoma Stage IV
Phase 2Cutaneous Melanoma
Phase 2Lung Cancer, Non-small Cell
Phase 2Lung Cancer Metastatic
Phase 2Solid Tumor, Adult
Phase 2Advanced Cancer
Phase 2Lung Cancer (NSCLC)
UnknownIndication pending review
Catalyst Calendar
DEC
ReadoutKB801
“A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects With Stage 2 or 3 Neurotrophic Keratitis — primary completion 2026-12”
DEC
ReadoutKB803
“A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa — primary completion 2026-12”
FEB
ReadoutKB707
“KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs — primary completion 2027-02”
JUL
ReadoutKB707
“A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies — primary completion 2027-07”
Past (3)
JUL 09
Conf.KB801
“the Company announced in the press release that it would host a conference call and webcast at 8:30 a.m. ET on July 9, 2025, to discuss neurotrophic keratitis, the Company's KB801 program, and the clinical study design”
JUL 24
ReadoutKB304
“positive safety and efficacy results for the Phase 1 study of KB304 for the treatment of moderate to severe wrinkles of the décolleté”
JUL 24
Conf.KB304
“the Company announced in the press release that it would host a conference call and webcast at 4:30 p.m. ET on July 24, 2025, to discuss the results of the study, the KB304 clinical development program”